FDA Brief

Warning letters Food

FDA warning letter to

LXR Biotech, LLC

MediumIssued Dec 23, 2025Posted Jan 13Human Foods Program

FDA warns LXR Biotech over CGMP (manufacturing quality rules) failures for Eternal Energy supplements, making them adulterated (legally unfit as made).

What happened

FDA inspected LXR Biotech's Rochester Hills, Michigan facility from February 25 to March 12, 2025 and issued a Form FDA 483 (inspection observations). FDA found CGMP violations for Eternal Energy Grape and Tropical Punch, including missing finished-product specifications and inadequate identity specifications and testing.

What FDA found

  1. The firm did not establish finished-product specifications for identity, purity, strength, and composition, and did not include some ingredients used in the products.

    21 CFR 111.70(e)
  2. The firm's identity specifications for two ingredients did not uniquely confirm each ingredient because other substances could meet the same criteria.

    21 CFR 111.70(b)(1)
  3. The firm did not ensure its identity tests were appropriate and scientifically valid; management did not know whether the supplier-provided reference standard was valid.

    21 CFR 111.75(h)(1)
  4. The firm also must verify that established product specifications are met.

    21 CFR 111.73 and 21 CFR 111.75

What FDA wants

FDA asks LXR Biotech to reply in writing within 15 working days with the specific steps taken to address the violations, how recurrence will be prevented, and related documentation; if corrective actions cannot be completed in that time, state the reason and the timeframe.

Who should pay attention

  • dietary supplement brands using contract manufacturers
  • companies sourcing energy supplement premixes
  • supplement quality and regulatory teams

This is a summary. Read the original letter on fda.gov.

LXR Biotech, LLC's FDA history

  1. LXR Biotech, LLC

    CGMP/Finished Pharmaceuticals/Adulterated

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk